Background: The treatment of patients with advanced hepatic hilar duct carcinoma is a challenging problem. The current study was performed to evaluate the outcome of patients with advanced hepatic hilar duct carcinoma who received external beam radiotherapy (EBRT) combined with transarterial chemotherapy and infusion of a vasoconstrictor.
Methods: Between April 1993 and December 2002, 23 patients with histopathologically confirmed hilar duct carcinoma entered the study. The median total dose of EBRT was 41.4 grays (Gy). Transarterial chemotherapy was performed twice during EBRT. It was comprised of an infusion of a cocktail of 20 mg of epirubicin, 10 mg of mitomycin C, and 500 mg of 5-fluorouracil and was administered 1 minute after injection of epinephrine via a catheter introduced in the hepatic arteries. After the combined treatment, the patients underwent biliary endoprosthesis after evaluation of the initial response to treatment by percutaneous transhepatic cholangiography (PTC). The initial responses based on PTC were classified into four categories: CR, no stenosis; PR, relief of stenosis/obstruction; NC, no change; and PD, progressive stenosis/obstruction. The outcome parameters were survival rates and time, as well as frequency and type of complications.
Results: Excluding 1 patient who discontinued the treatment, the initial responses of 22 patients were 1 CR (5%), 8 PR (36%), 11 NC (50%), and 2 PD (9%). The response rate was 41%. The overall survival rates at 1 year, 2 years, and 3 years after treatment were 59%, 36%, and 18%, respectively.
Conclusions: The combination of radiotherapy, transarterial infusion chemotherapy, and concurrent infusion of a vasoconstrictor can be delivered safely with good efficacy for patients with advanced hilar duct carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.20265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endoscopic Stenting of a Fully Covered Self-Expandable Metal Stent with a Hole in Each Cavity in Malignant Hilar Biliary Obstruction: A Preclinical Proof-of-Concept Study and Initial Human Experience.
Dig Dis Sci
January 2025
Digestive Disease Center, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Background And Aim: Stent placement for biliary drainage in patients with malignant hilar biliary obstruction (MHBO) has been a topic of long-standing debate, and the best approach remains controversial. Therefore, we aimed to evaluate the efficacy, safety, and removability of multi-hole fully covered self-expandable metal stents (MH-FCSEMSs) in a preclinical experiment using swine hilar bile duct obstruction (HBDO) models and to assess the feasibility and safety of stent placement in patients with MHBO.
Methods: Three minipigs underwent endoscopic retrograde cholangiopancreatography (ERCP)-guided endobiliary-radio frequency ablation (EB-RFA) to establish Bismuth type II hilar bile duct stenosis models.
Combined diagnosis of signet ring cell carcinoma of hilar cholangiocarcinoma by three endoscopes.
Rev Esp Enferm Dig
January 2025
Biliary and Pancreatic Endoscopic Surgery, The Second Hospital of Hebei Medical University, china.
Signet-ring cell carcinoma is a poorly differentiated adenocarcinoma with a high degree of malignancy, which rarely occurs in hilar bile duct. As far as I know, this is the third signet-ring cell carcinoma of hilar cholangiocarcinoma found so far. We used endoscopic ultrasound（EUS） and per-oral cholangioscopy（POCPS） to make a definite diagnosis.
View Article and Find Full Text PDFOPTIMIZING PERIOPERATIVE CARE FOR PERIHILAR CHOLANGIOCARCINOMA: THE CRUCIAL ROLE OF MULTIDISCIPLINARY MANAGEMENT, NEOADJUVANT THERAPY, AND INTERVENTIONAL RADIOLOGY.
Arq Bras Cir Dig
January 2025
Pontificia Universidad Católica de Chile, Department of Digestive Surgery - Santiago, Chile.
Background: Perihilar cholangiocarcinoma presents unique challenges in perioperative management, requiring a comprehensive approach to optimize patient outcomes.
Aims: This case study focuses on the multidisciplinary management and innovative interventions performed in the perioperative care of a patient with hilar cholangiocarcinoma.
Methods: A comprehensive assessment and treatment strategy involving neoadjuvant therapy and interventional radiology techniques were implemented.
Current advance in comprehensive management of hilar cholangiocarcinoma and navigation in surgery: non-systematic reviews.
Int J Surg
December 2024
Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- Hilar cholangiocarcinoma (h-CCA) is a challenging cancer that starts in the bile duct's epithelial cells, often diagnosed at advanced stages, leading to high mortality rates.
- For patients who can't undergo surgery, systemic therapy and emerging immunotherapies provide new hope, while radical surgery remains the best option for improved survival.
- Advancements in imaging technologies and techniques, such as near-infrared fiberscopes, are enhancing surgeons' ability to achieve tumor-free margin resections during operations.
Assessing the Feasibility and Diagnostic Value of Percutaneous Transhepatic Cholangioscopy Biopsy for Biliary Strictures.
Cardiovasc Intervent Radiol
January 2025
Radiology Department, Hanoi Medical University, 1st Ton That Tung Streets, Dong Da, Hanoi, 10000, Vietnam.
Objective: To evaluate the feasibility and diagnostic value of percutaneous transhepatic cholangioscopy biopsy (PTCB) for identifying the causes of biliary strictures.
Methods: This retrospective study included 34 patients (18 females and 16 males), with a mean age of 59.4 ± 13 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!